The Diacylglycerol O Acyltransferase 2 pipeline drugs market research report outlays comprehensive information on the Diacylglycerol O Acyltransferase 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Diacylglycerol O Acyltransferase 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Gastrointestinal, and Metabolic Disorders which include the indications Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), and Type 2 Diabetes. It also reviews key players involved in Diacylglycerol O Acyltransferase 2 targeted therapeutics development with respective active and dormant or discontinued products.
The Diacylglycerol O Acyltransferase 2 pipeline targets constitutes close to six molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, and Discovery stages are 3, 2, and 1 respectively.
Diacylglycerol O Acyltransferase 2 overview
Diacylglycerol O Acyltransferase 2 is an enzyme that in humans is encoded by a gene DGAT2. This enzyme plays a crucial role in triglyceride synthesis, a process involved in lipid metabolism in which diacylglycerol is covalently bound to long chain fatty acyl-CoAs. Triglycerides are a type of lipid that serves as a major storage form of energy in the body. Triglycerides are stored in adipose tissue and can be mobilized to provide energy when needed. DGAT2, along with DGAT1 (another isoform of diacylglycerol O-acyltransferase), contributes to lipid homeostasis by regulating the balance between lipid storage and utilization in various tissues. Dysregulation of triglyceride metabolism, including the activity of DGAT2, has been implicated in metabolic disorders such as obesity, insulin resistance, and non-alcoholic fatty liver disease (NAFLD).
For a complete picture of Diacylglycerol O Acyltransferase 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
